TEVA is coming


an AstraZeneca too:

AstraZeneca says FDA accepts application for Epanova
AstraZeneca announced that the FDA has accepted for review a New Drug Application for Epanova, an investigational compound for the treatment for patients with severe hypertriglyceridaemia. The NDA submission for Epanova was filed by Omthera, now a wholly-owned subsidiary of AstraZeneca.T he Prescription Drug User Fee Act goal date for the FDA is May 5, 2014.
 
























from the canaccord conference last month: your President of Amarin, Thero:
At the same time, we're entertaining proposals from third parties, that could give us greater reach or frequency if we need it. It's too early for us to have to make that decision. At this point in time, we've launched the MARINE indication in January and we made our final decisions relative to sales forcing in December. And we don't need to make that final decision at this stage relative to the ANCHOR indication. But we're also cognizant of the fact that, if we were to do a deal for example co-promote deal, but we are not doing it just for the splash or a news headline.

If we are going to do it it's got to be deal that there is strong merit into it for both sides, there have been too many co-promotes that the partner write the co-tells and doesn't deliver. And we are really looking for value not just the -- the metric is in maximizing the revenues, metric is maximizing value per share. So, we're evaluating a range of possibilities from doing it ourselves to doing with somebody else, but we don't need to be making that decision yet.
 


















Idiot alert!

A sphincter says, "Idiot alert", when they don't have a rebuttal. Vascepa will be the only Omega-3 indicated for high TG's (200-499), which will lead to more Tier 2 managed care coverage for Vascepa and more evidence keeps piling on that EPA and not DHA has CV benefits. Read on if you can understand what's contained in this review:

"Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio" Journal of Atherosclerosis and Thrombosis Vol.20 by Haruo Ohnishi and Yasushi Saito:

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_18002/_pdf
 






A sphincter says, "Idiot alert", when they don't have a rebuttal. Vascepa will be the only Omega-3 indicated for high TG's (200-499), which will lead to more Tier 2 managed care coverage for Vascepa and more evidence keeps piling on that EPA and not DHA has CV benefits. Read on if you can understand what's contained in this review:

"Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio" Journal of Atherosclerosis and Thrombosis Vol.20 by Haruo Ohnishi and Yasushi Saito:

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_18002/_pdf

I love when the investors pollute this board looking to sell their company to people here. Remember, >50% drop in equity prices in one year. LOL
 












A sphincter says, "Idiot alert", when they don't have a rebuttal. Vascepa will be the only Omega-3 indicated for high TG's (200-499), which will lead to more Tier 2 managed care coverage for Vascepa and more evidence keeps piling on that EPA and not DHA has CV benefits. Read on if you can understand what's contained in this review:

"Eicosapentaenoic Acid (EPA) Reduces Cardiovascular Events: Relationship with the EPA/Arachidonic Acid Ratio" Journal of Atherosclerosis and Thrombosis Vol.20 by Haruo Ohnishi and Yasushi Saito:

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_18002/_pdf

Well funny that the combination of EPA/DHA reduced death, but the EPA only reduced non fatal events.
Also it suggest in the article that DHA does play a role in cardiovascular disease.